These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23825155)

  • 1. Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression.
    Zhao Y; Kumbrink J; Lin BT; Bouton AH; Yang S; Toselli PA; Kirsch KH
    Carcinogenesis; 2013 Dec; 34(12):2880-90. PubMed ID: 23825155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A truncated phosphorylated p130Cas substrate domain is sufficient to drive breast cancer growth and metastasis formation in vivo.
    Kumbrink J; de la Cueva A; Soni S; Sailer N; Kirsch KH
    Tumour Biol; 2016 Aug; 37(8):10665-73. PubMed ID: 26867768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
    Peng M; Ball-Kell SM; Tyner AL
    Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer.
    Miwa HE; Koba WR; Fine EJ; Giricz O; Kenny PA; Stanley P
    Glycobiology; 2013 Dec; 23(12):1477-90. PubMed ID: 24037315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
    Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
    Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p130Cas alters the differentiation potential of mammary luminal progenitors by deregulating c-Kit activity.
    Tornillo G; Elia AR; Castellano I; Spadaro M; Bernabei P; Bisaro B; Camacho-Leal Mdel P; Pincini A; Provero P; Sapino A; Turco E; Defilippi P; Cabodi S
    Stem Cells; 2013 Jul; 31(7):1422-33. PubMed ID: 23592522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.
    Mao SPH; Park M; Cabrera RM; Christin JR; Karagiannis GS; Oktay MH; Zaiss DMW; Abrams SI; Guo W; Condeelis JS; Kenny PA; Segall JE
    Breast Cancer Res; 2018 Oct; 20(1):131. PubMed ID: 30367629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.
    Cowell LN; Graham JD; Bouton AH; Clarke CL; O'Neill GM
    Oncogene; 2006 Dec; 25(58):7597-607. PubMed ID: 16799644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene.
    Webster MA; Cardiff RD; Muller WJ
    Proc Natl Acad Sci U S A; 1995 Aug; 92(17):7849-53. PubMed ID: 7544006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.
    Provenzano PP; Inman DR; Eliceiri KW; Beggs HE; Keely PJ
    Am J Pathol; 2008 Nov; 173(5):1551-65. PubMed ID: 18845837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Novel Crk-associated Substrate (p130Cas) Variants with Functionally Distinct Focal Adhesion Kinase Binding Activities.
    Kumbrink J; Soni S; Laumbacher B; Loesch B; Kirsch KH
    J Biol Chem; 2015 May; 290(19):12247-55. PubMed ID: 25805500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
    Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
    Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preneoplastic mammary tumor markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice.
    Niemeyer CC; Spencer-Dene B; Wu JX; Adamson ED
    Int J Cancer; 1999 May; 81(4):588-91. PubMed ID: 10225449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of tumor fatty acids, through overexpression or loss of thyroid hormone responsive protein spot 14 is associated with altered growth and metastasis.
    Wellberg EA; Rudolph MC; Lewis AS; Padilla-Just N; Jedlicka P; Anderson SM
    Breast Cancer Res; 2014 Dec; 16(6):481. PubMed ID: 25472762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells.
    Bisaro B; Montani M; Konstantinidou G; Marchini C; Pietrella L; Iezzi M; Galiè M; Orso F; Camporeale A; Colombo SM; Di Stefano P; Tornillo G; Camacho-Leal MP; Turco E; Taverna D; Cabodi S; Amici A; Defilippi P
    Breast Cancer Res; 2012 Oct; 14(5):R137. PubMed ID: 23098208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan.
    Gibby K; You WK; Kadoya K; Helgadottir H; Young LJ; Ellies LG; Chang Y; Cardiff RD; Stallcup WB
    Breast Cancer Res; 2012 Apr; 14(2):R67. PubMed ID: 22531600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model.
    Roselli S; Kahl RG; Copeland BT; Naylor MJ; Weidenhofer J; Muller WJ; Ashman LK
    BMC Cancer; 2014 Jul; 14():509. PubMed ID: 25012362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
    Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
    J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
    Corsino P; Davis B; Law M; Chytil A; Forrester E; Nørgaard P; Teoh N; Law B
    Cancer Res; 2007 Apr; 67(7):3135-44. PubMed ID: 17409420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.